CY1123607T1 - A JAK-INHIBITING COMPOUND CRYSTAL - Google Patents
A JAK-INHIBITING COMPOUND CRYSTALInfo
- Publication number
- CY1123607T1 CY1123607T1 CY20201101142T CY201101142T CY1123607T1 CY 1123607 T1 CY1123607 T1 CY 1123607T1 CY 20201101142 T CY20201101142 T CY 20201101142T CY 201101142 T CY201101142 T CY 201101142T CY 1123607 T1 CY1123607 T1 CY 1123607T1
- Authority
- CY
- Cyprus
- Prior art keywords
- effect
- jak
- inhibiting compound
- compound crystal
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Ένα αντικείμενο της παρούσας εφεύρεσης είναι να παρέχει μια ένωση με εξαιρετική ανασταλτική δράση στην JAK1. Η ένωση της εφεύρεσης έχει ανασταλτική δράση στην JAK1, και έτσι, ανοσοκατασταλτική επίδραση, αντιφλεγμονώδη επίδραση, αντιπολλαπλασιαστική επίδραση και ούτω καθεξής, και είναι χρήσιμη στη θεραπεία των ασθενειών, για παράδειγμα, ρευματοειδής αρθρίτιδα, φλεγμονώδης νόσος του εντέρου, ψωρίαση, αγγειίτιδα, βρογχικό άσθμα, χρόνια αποφρακτική πνευμονοπάθεια, ηωσινοφιλική ιγμορίτιδα και ρινικός πολύποδας.An object of the present invention is to provide a compound with excellent JAK1 inhibitory activity. The compound of the invention has an inhibitory effect on JAK1, and thus, immunosuppressive effect, anti-inflammatory effect, anti-proliferative effect and so on, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis, vasculitis, bronchial asthma , chronic obstructive pulmonary disease, eosinophilic sinusitis and nasal polyp.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016039315 | 2016-03-01 | ||
| PCT/JP2017/007594 WO2017150477A1 (en) | 2016-03-01 | 2017-02-28 | Crystal of compound having jak-inhibiting activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123607T1 true CY1123607T1 (en) | 2022-03-24 |
Family
ID=59743962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201101142T CY1123607T1 (en) | 2016-03-01 | 2020-12-02 | A JAK-INHIBITING COMPOUND CRYSTAL |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10822350B2 (en) |
| EP (1) | EP3424930B1 (en) |
| JP (1) | JP6791239B2 (en) |
| KR (1) | KR102653231B1 (en) |
| CN (1) | CN108699082B (en) |
| BR (1) | BR112018016523B1 (en) |
| CA (2) | CA3206830A1 (en) |
| CY (1) | CY1123607T1 (en) |
| DK (1) | DK3424930T3 (en) |
| ES (1) | ES2844978T3 (en) |
| HR (1) | HRP20210062T1 (en) |
| HU (1) | HUE051615T2 (en) |
| LT (1) | LT3424930T (en) |
| MX (1) | MX2018010334A (en) |
| PL (1) | PL3424930T3 (en) |
| PT (1) | PT3424930T (en) |
| RS (1) | RS61238B1 (en) |
| RU (1) | RU2705721C1 (en) |
| SI (1) | SI3424930T1 (en) |
| TW (1) | TWI712604B (en) |
| WO (1) | WO2017150477A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI712604B (en) * | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | Crystal of compound with JAK inhibitory effect |
| CA3192219A1 (en) * | 2020-09-14 | 2022-03-17 | Heiko HABERMULLER | N-heterocyclic compounds used as nitrification inhibitor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3600390A1 (en) | 1986-01-09 | 1987-07-16 | Hoechst Ag | DIARYLALKYL-SUBSTITUTED ALKYLAMINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCTS CONTAINING THE SAME |
| BRPI0506817A (en) | 2004-01-12 | 2007-05-29 | Cytopia Res Pty Ltd | selective kinase inhibitors |
| KR20080063809A (en) * | 2005-09-30 | 2008-07-07 | 버텍스 파마슈티칼스 인코포레이티드 | Deazapurines useful as inhibitors of janus kinases |
| EP2537849A3 (en) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| ES2602577T3 (en) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| JO3041B1 (en) | 2008-07-25 | 2016-09-05 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010070060A1 (en) * | 2008-12-19 | 2010-06-24 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
| TWI462920B (en) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
| ES2461967T3 (en) | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Pyrrolo [2,3-d] pyrimidine compounds |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| JP2011136925A (en) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | Nitrogen-containing bicyclic compound |
| KR20140015162A (en) | 2010-01-12 | 2014-02-06 | 에프. 호프만-라 로슈 아게 | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| UY33213A (en) | 2010-02-18 | 2011-09-30 | Almirall Sa | PIRAZOL DERIVATIVES AS JAK INHIBITORS |
| WO2012022045A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| WO2012037132A1 (en) | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Phtalazine derivatives as jak1 inhibitors |
| WO2012054364A2 (en) | 2010-10-22 | 2012-04-26 | Merck Sharp & Dohme Corp. | Bicyclic diamines as janus kinase inhibitors |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| WO2013025628A1 (en) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| TWI679205B (en) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | Pyrazolothiazole compounds and medicine |
| TWI712604B (en) * | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | Crystal of compound with JAK inhibitory effect |
-
2017
- 2017-02-08 TW TW106104074A patent/TWI712604B/en active
- 2017-02-28 SI SI201730521T patent/SI3424930T1/en unknown
- 2017-02-28 PT PT177599438T patent/PT3424930T/en unknown
- 2017-02-28 US US16/077,889 patent/US10822350B2/en active Active
- 2017-02-28 CN CN201780014551.5A patent/CN108699082B/en active Active
- 2017-02-28 JP JP2018503309A patent/JP6791239B2/en active Active
- 2017-02-28 MX MX2018010334A patent/MX2018010334A/en unknown
- 2017-02-28 KR KR1020187027122A patent/KR102653231B1/en active IP Right Grant
- 2017-02-28 BR BR112018016523-9A patent/BR112018016523B1/en active IP Right Grant
- 2017-02-28 RU RU2018134041A patent/RU2705721C1/en active
- 2017-02-28 WO PCT/JP2017/007594 patent/WO2017150477A1/en active Application Filing
- 2017-02-28 DK DK17759943.8T patent/DK3424930T3/en active
- 2017-02-28 CA CA3206830A patent/CA3206830A1/en active Pending
- 2017-02-28 ES ES17759943T patent/ES2844978T3/en active Active
- 2017-02-28 LT LTEP17759943.8T patent/LT3424930T/en unknown
- 2017-02-28 PL PL17759943T patent/PL3424930T3/en unknown
- 2017-02-28 HU HUE17759943A patent/HUE051615T2/en unknown
- 2017-02-28 CA CA3015464A patent/CA3015464C/en active Active
- 2017-02-28 EP EP17759943.8A patent/EP3424930B1/en active Active
- 2017-02-28 RS RS20201509A patent/RS61238B1/en unknown
-
2020
- 2020-09-29 US US17/035,947 patent/US11377453B2/en active Active
- 2020-12-02 CY CY20201101142T patent/CY1123607T1/en unknown
-
2021
- 2021-01-13 HR HRP20210062TT patent/HRP20210062T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102653231B1 (en) | 2024-04-01 |
| WO2017150477A1 (en) | 2017-09-08 |
| EP3424930B1 (en) | 2020-11-04 |
| US20190048023A1 (en) | 2019-02-14 |
| TWI712604B (en) | 2020-12-11 |
| JPWO2017150477A1 (en) | 2018-12-27 |
| EP3424930A4 (en) | 2019-07-10 |
| PL3424930T3 (en) | 2021-05-04 |
| ES2844978T3 (en) | 2021-07-23 |
| LT3424930T (en) | 2021-01-11 |
| SI3424930T1 (en) | 2021-01-29 |
| HRP20210062T1 (en) | 2021-03-05 |
| TW201731855A (en) | 2017-09-16 |
| CA3015464C (en) | 2024-04-23 |
| BR112018016523B1 (en) | 2024-02-06 |
| RU2705721C1 (en) | 2019-11-11 |
| CN108699082B (en) | 2021-04-09 |
| US10822350B2 (en) | 2020-11-03 |
| EP3424930A1 (en) | 2019-01-09 |
| BR112018016523A2 (en) | 2018-12-26 |
| MX2018010334A (en) | 2018-11-09 |
| DK3424930T3 (en) | 2021-01-11 |
| PT3424930T (en) | 2020-12-04 |
| HUE051615T2 (en) | 2021-03-01 |
| RS61238B1 (en) | 2021-01-29 |
| US20210017191A1 (en) | 2021-01-21 |
| JP6791239B2 (en) | 2020-11-25 |
| KR20180116341A (en) | 2018-10-24 |
| CN108699082A (en) | 2018-10-23 |
| CA3206830A1 (en) | 2017-09-08 |
| US11377453B2 (en) | 2022-07-05 |
| CA3015464A1 (en) | 2017-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123607T1 (en) | A JAK-INHIBITING COMPOUND CRYSTAL | |
| CY1122322T1 (en) | ANTI-IL-17A ANTIBODIES AND THEIR USE IN THE THERAPEUTIC TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | |
| CY1123320T1 (en) | PYRAZOLOTHIAZOLE COMPOUND AND DRUG CONTAINING IT | |
| CY1126056T1 (en) | NEW AMINOPYRIMIDINE DERIVATIVES | |
| CY1123369T1 (en) | COMPOSITIONS AND METHODS FOR REGULATING THE EXPRESSION OF APOLYPOPROTEIN (A) | |
| CY1126038T1 (en) | ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS | |
| CY1121292T1 (en) | NEW HETEROCYCLIC DERIVATIVES AND THEIR USES | |
| UY28153A1 (en) | P2X7 RECEIVER BENZAMID INHIBITORS | |
| MA52900A (en) | SMALL MOLECULE INHIBITORS OF THE JAK FAMILY OF KINASES | |
| BR112018069526A2 (en) | portable roller equipment | |
| FR3056251B1 (en) | REINFORCED EXHAUST CASE AND METHOD OF MANUFACTURE | |
| EP3937937A4 (en) | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine | |
| FR3046951B1 (en) | PROCESS FOR MANUFACTURING A PIECE OF A TURBOMACHINE AND PIECE PRODUCED THEREBY | |
| BR112018071289A2 (en) | process for the manufacture of 6-alkynyl pyridine derivatives | |
| Park et al. | A Study on the Current Status of Building Envelope in detached houses of near Local Cities-with Staff of Small-sized Architectural Design Firms in Gwangju and Jeonnam | |
| Pociask et al. | Il-22/Il-22 Binding Protein (il-22ra2) Balance Is Critical For The Resolution Of Influenza Induced Lung Pathology | |
| Kaethler | Please Mind the Suburbs | |
| UA114982C2 (en) | LOCAL TREATMENT OF EKZEMA | |
| TH60336S1 (en) | Metal cross-section | |
| TH60337S1 (en) | Metal cross-section | |
| ES2753602R1 (en) | DIFFERENTIAL BIOMARKERS OF ASTHMA | |
| IT201700025273A1 (en) | CO-CRYSTALS OF VINPOCETIN AND THEIR PREPARATION PROCESS | |
| Pawar et al. | Conformational comparison of cyclic α</inf> 3<//inf> βtetrapeptide vs. α</inf> 3<//inf> β pentapeptide | |
| Lem | Misperceived graphs: The case of bar charts, histograms, and box plots | |
| UA112751U (en) | METHOD OF TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE IN conjunction with Osteoarthritis |